Banner - NPPA Connect

NP/PA Connect
News
Media
Conferences
Events
Publication
CME/CE
Resources
Editorial Advisory Board
Partners
Subscribe

Opinion|Videos|December 19, 2024

Addressing Psychological and Social Impacts of Pediatric Vitiligo

Author(s)Lawrence Eichenfield, MD

Key Takeaways

Larry Eichenfield, MD, discusses how pediatric vitiligo can profoundly impact a child’s mental health, self-esteem, and social relationships, requiring a comprehensive care approach that includes psychological support, family counseling, and strategies to help children navigate peer interactions and build resilience.

Episodes in this series

1 KOL is featured in this series.

EP. 1 Collaborating With Communities to Manage Pediatric Vitiligo

1 KOL is featured in this series.

EP. 2 Anticipating Advances for Pediatric Vitiligo

1 KOL is featured in this series.

EP. 3 Telehealth and Research Strides for Young Patients

1 KOL is featured in this series.

EP. 4 Managing Expectations and Holistically Treating Patients With Vitiligo

1 KOL is featured in this series.

EP. 5 Vitiligo Repigmentation Challenges and Evaluating Treatment Success

1 KOL is featured in this series.

EP. 6 Clinical Presentation

1 KOL is featured in this series.

EP. 7 Promising and Emerging Therapies in the Vitiligo Landscape

1 KOL is featured in this series.

EP. 8 The JAK Revolution in Vitiligo

1 KOL is featured in this series.

EP. 9 Balancing Safety and Efficacy With Key Data

1 KOL is featured in this series.

EP. 10 Vitiligo Treatment Patterns and Pearls for Adults Versus Pediatric Patients

1 KOL is featured in this series.

EP. 11 Tailoring Treatments and Counseling Patients With Pediatric Vitiligo

1 KOL is featured in this series.

EP. 12 Safety, Efficacy, and Treatment Adherence in Young Patients With Vitiligo

EP. 13 Treatment Insights and Evolving Care Options in Vitiligo

EP. 13 Treatment Insights and Evolving Care Options in Vitiligo

1 KOL is featured in this series.

EP. 14 Key Differences in Onset, Progression, Diagnosis, and Treatment of Pediatric Vitiligo

1 KOL is featured in this series.

EP. 15 Addressing Psychological and Social Impacts of Pediatric Vitiligo

1 KOL is featured in this series.

EP. 16 Promoting Open and Positive Dialogue With Families of Patients With Pediatric Vitiligo

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Related Content

David Rosmarin, MD

David Rosmarin, MD, on CHE Heterogeneity and Unmet Needs in AD and Vitiligo

ByDavid Rosmarin, MD,Kaitlyn Bader, Assistant Managing Editor

June 19th 2026

Tips for Managing Pain and Local Skin Reactions During Photodynamic Therapy

ByNeal Bhatia, MD,Kaitlyn Bader, Assistant Managing Editor

May 27th 2026

Dermatology Times Spot Test: May 23, 2026

ByMarie Bosslett, Assistant Editor

May 23rd 2026

Field-Directed PDT May Improve Long-Term Management of Actinic Damage and Superficial BCC

ByNeal Bhatia, MD,Kaitlyn Bader, Assistant Managing Editor

May 20th 2026

Genetic Study Links CD4+ T-Cell Subsets to Reduced Vitiligo Risk

ByMarie Bosslett, Assistant Editor

May 19th 2026

Latest CME

Revolutionizing Atopic Dermatitis (RAD) Conference 2026

In-Person Event

Revolutionizing Atopic Dermatitis (RAD) Conference 2026

June 17-19, 2026

Clinical Consultations™: Providing Holistic Care for Complex Cases of Psoriasis with Cardiovascular Comorbidities

Clinical Consultations™: Providing Holistic Care for Complex Cases of Psoriasis with Cardiovascular Comorbidities

Brittany Weber MD, PhD, FACC, FAHA; Lourdes M. Perez-Chada MD, MMSc

Understanding Topical Steroid Withdrawal (TSW) in Patients With Atopic Dermatitis (AD)

Understanding Topical Steroid Withdrawal (TSW) in Patients With Atopic Dermatitis (AD)

Diego Ruiz Dasilva, MD, FAAD; Brad Glick, DO, MPH. FAAD; Peter Lio, MD

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

Andrew Alexis, MD, MPH; Leon Kircik, MD

Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis

Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis

Johann Gudjonsson, MD, PhD; Christopher Bunick, MD, PhD

Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient

Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient

Douglas DiRuggiero, DMSc, MHS, PA-C; Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP

Burst CME™: Optimizing Care for Patients with Psoriasis – Incorporating a Buy-and-Bill Model for Biologic Agents into Dermatological Practice

Burst CME™: Optimizing Care for Patients with Psoriasis – Incorporating a Buy-and-Bill Model for Biologic Agents into Dermatological Practice

Jerry Bagel, MD, MS

Patient, Provider, and Caregiver Connection™: Addressing Patient Challenges With Holistic Approaches to Vitiligo Management

Patient, Provider, and Caregiver Connection™: Addressing Patient Challenges With Holistic Approaches to Vitiligo Management

Andrew F. Alexis, MD, MPH; Chesahna Kindred, MD, MBA, FAAD

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Hadar Lev-Tov, MD; Martina Porter, MD

Trending on Dermatology Times

Chronic Hand Eczema: Treatment Gaps, New Options, and Clinical Trial End Points

Mona Shahriari, MD, FAAD: Matching the Right AD Therapy to the Right Patient

David Rosmarin, MD, on CHE Heterogeneity and Unmet Needs in AD and Vitiligo

Clear Health Launches Topical Isotretinoin Acne Treatment Without iPLEDGE Requirements

First HA Injectable for Neck Wrinkles Cleared by FDA